Thermo Fisher Scientific

Advancing breakthroughs to treat rare diseases With Rare Disease Day on February 28, I’ve been reflecting on the millions of people worldwide living with serious, complex and often devastating conditions that historically have been so challenging to treat. What gives me real optimism is how rapidly the therapeutic landscape is evolving, moving beyond traditional modalities toward advanced therapies designed to address disease biology with unprecedented precision. That momentum is expanding beyond oncology into areas such as neurodegenerative and autoimmune diseases. For example, CAR-T cell therapy is being explored in rare conditions like generalized myasthenia gravis, where early programs are evaluating whether targeted immune reset strategies could meaningfully alter disease course. Gene editing technologies, including CRISPR-based approaches, are also advancing, with the potential to address underlying disease drivers directly. At the same time, advances in genomics, multi-omics, and sophisticated diagnostic technologies are transforming how rare diseases are identified, how patients are stratified, and how individuals are matched to the therapies most likely to benefit them. While the science is progressing quickly, the work ahead remains substantial. These therapies are complex to develop, manufacture, and deliver at scale, and ensuring consistent quality, regulatory readiness and broad patient access remains critical. At Thermo Fisher Scientific, we are committed to being a trusted partner to the innovators advancing this frontier. From early research and process development to clinical readiness and manufacturing scale-up, our technologies, services and expertise help developers move with speed and rigor. We also enable companion diagnostics development and invest in capabilities such as our Advanced Therapies Collaboration Centers to help accelerate progress. Our Mission is to enable our customers to make the world healthier, cleaner, and safer. On Rare Disease Day, our Mission feels especially meaningful. We’re proud to stand with the researchers, doctors and advocacy groups working to redefine what is possible in treating rare diseases and enable a brighter future for patients and their families.

Today we introduced a new laboratory developed test to help transplant patients receive the right dose of critical anti-rejection medication sooner. For transplant recipients, finding the right dose of tacrolimus, a commonly prescribed immunosuppressive drug, as early as possible can be life-changing. If the dose is too low, the body may reject the new organ. If it is too high, patients face increased risks of organ injury, infection and other serious complications. Patients process tacrolimus differently based in part on their genetics, making standard dosing approaches difficult and often leading to repeated adjustments during the most vulnerable period after transplant. Our new TacroType™ Pharmacogenetic Test provides genetic insights that can help clinicians better understand how an individual patient is likely to metabolize tacrolimus—supporting more informed dosing decisions from the start and helping reduce the trial-and-error approach that many patients experience today. Learn more: https://lnkd.in/gbm86Cr8

Your cells are constantly sending signals and proteins are some of the most important ones. Proteins are the workhorses in our bodies that regulate function, and they often change in the presence of disease in ways that offer scientists valuable clues in real time. That’s the idea behind proteomics: studying proteins to help better understand disease, identify potential biomarkers and explore new paths that can inform research into future therapies. Thermo Fisher Scientific supports customers at the forefront of proteomics every day with expertise and complementary tools, including our mass spectrometry platforms and Olink® proximity extension assays, to help move deep protein insights from discovery to real-world impact. Because behind every newly discovered protein lies the potential to bring us closer to a future of earlier diagnoses, more precise treatments and renewed hope for patients and their families. Watch the video to learn more about the potential of proteomics.

14-year-old Miles Wu took a decades-old origami fold and treated it like an engineering system, designing 54 variations, running 108 trials and testing how much each pattern could hold before it failed. One of his folded structures supported more than 10,000× its own weight, "the equivalent of a New York City taxicab supporting the weight of over 4,000 elephants," he told Smithsonian Magazine. Miles is continuing to test folds and believes insights from this work could help inform the design of emergency shelters for natural disasters. His project earned the $25,000 top prize at the 2025 Thermo Fisher Scientific Junior Innovators Challenge, showing what’s possible when curiosity, careful measurement and persistence meet opportunity. Learn more about Miles and his plans for the future: https://lnkd.in/dB62z9aR Society for Science

When our Mission to enable our customers to make the world healthier, cleaner and safer is clear, teams move with focus. That’s how Surendran Krishnamurthi (SK), General Manager, Thermo Fisher Scientific Singapore, views his role as a leader, helping teams start with the “why,” then building the conditions for people to take ownership and keep learning. “I encourage accountability, empowering team members to take ownership of their work… This fosters responsibility and builds confidence and trust, both within the team and with our customers and stakeholders,” says SK. In a fast-moving environment, SK emphasizes agility and collaboration, staying curious, embracing change and valuing different perspectives to reach shared goals. And along the way, he helps his team celebrate the “small wins” that power everyday progress, alongside the breakthroughs that move science forward. Learn more about SK’s leadership style and life at Thermo Fisher: https://lnkd.in/dcJmgdkR

The 5000L manufacturing scale, as part of Fujifilm’s mid-scale capacity expansion, can help fundamentally change how life-changing therapies move from the lab to patients who need them. That was a key theme at the opening of FUJIFILM Biotechnologies’ expanded Teesside facilities in the U.K., where Thermo Fisher’s Natraj Ram joined a panel with Steve Bates OBE FMedSci, Maja Herold Pedersen, Jonathan Haigh and Steve Bagshaw to discuss what advanced biomanufacturing means for the U.K.’s growth in life sciences. Natraj shared how our 5,000-L DynaDrive™ technology helps Fujifilm scale manufacturing at mid-volume as part of a broader effort to expand capacity and flexibility for advanced therapies. Congratulations to everyone involved in this milestone for Fujifilm and the broader U.K. life sciences ecosystem. We’re grateful to support work that aims to accelerate progress for patients and families affected by conditions like Alzheimer’s disease, prostate cancer and rare diseases.

What is next in drug development? Our experts unpack what’s changing, from the potential impact of New Approach Methodologies to how AI is already delivering value today (and what could come next), in the latest edition of Serving Science.

On Valentine's Day, we celebrate our love for science! We are inspired every day by the innovators who make life-changing discoveries possible through relentless research and cutting-edge advancements. Thank you for all that you do to help shape a brighter future for all.

In the biopharma industry, our relationship with regulators is sacrosanct. As regulatory complexity and scrutiny continue to rise globally, I’ve been reflecting on how those relationships are built and sustained. It’s true that formal interactions matter. But when it comes down to it, real trust is earned every single day through the quality of our work. You simply cannot have a strong, trusted relationship with regulators without doing a great job on quality. The two are inseparable. Every site that designs, manufactures or distributes products for customers and patients has to get it right. Every time. We can’t take our foot off the gas when it comes to quality, because the consequences of getting it wrong are real: a wrong answer, a delayed diagnosis, a patient not getting the medicine they need. Our reputation with regulators is not abstract. It’s built decision by decision, signature by signature, action by action. That’s why I talk so much about the importance of Making Quality Personal at Thermo Fisher Scientific. When people understand how their individual work connects to patients and customers, quality stops being a requirement and becomes a responsibility. That’s the standard we have to hold ourselves to, every single day. 𝗪𝗵𝗮𝘁’𝘀 𝗮 𝗻𝗼𝗻-𝗻𝗲𝗴𝗼𝘁𝗶𝗮𝗯𝗹𝗲 𝗳𝗼𝗿 𝘆𝗼𝘂 𝗶𝗻 𝗯𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗿𝗲𝗹𝗮𝘁𝗶𝗼𝗻𝘀𝗵𝗶𝗽𝘀? 𝗟𝗲𝘁 𝗺𝗲 𝗸𝗻𝗼𝘄 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀.   #MakingQualityPersonal #QualityLeadership #RegulatoryAffairs 

On International Day of Women and Girls in Science, we celebrate innovators like Camila Gonzalez-Thompson. Camila earned a top award and $10,000 at the Thermo Fisher Scientific Junior Innovators Challenge for her work analyzing blood samples to help understand how the Dengue virus spreads in Puerto Rico, where she lives. Her results could contribute to targeted prevention strategies and increase public knowledge of how to protect younger, more vulnerable age groups from increased risk of infection. “Winning represents that young minds can contribute to real scientific questions and be taken seriously in the research community,” Camila said. “For me, it’s a reminder that dedication, curiosity, and hard work truly matter. Coming from Puerto Rico and being passionate about improving health in my community, this award encourages me to continue my research and pursue my goals,” says Camila. Join us today in honoring Camila and every woman and girl in science whose curiosity and pursuit of innovation help us tackle some of the world’s most pressing challenges. Society for Science